- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cushing syndrome
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 296KB)
Osilodrostat – March 2023
Osilodrostat: Tablet 1 mg, Tablet 5 mg, Tablet 10 mg; Isturisa®
Last updated
14 July 2023